Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures

Pediatric Allergy and Immunology

Volumn 18, Issue 1, 2007, Pages 47-57

  Pham Thi, Nhân ^b   Scheinmann, Pierre ^b   Fadel, Riad ^a   Combebias, Anne ^a   Andre, Claude ^a   Alt, R ^c   Basset Stheme, D ^c   Bouillot, F ^c   Bourrier, T ^c   Dakhil, J ^c   Dollois, B ^c   Gallen, C ^c   Greillier, P ^c   Grosclaude, M ^c   Herpin Richard, N ^c   Larchevesque, M ^c   Le Loet, C ^c   Leprince, F ^c   Paty, E ^c   Rufin, P ^c   Sabouraud, D ^c   Traube, C ^c   more..

^a Stallergenes SA   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c Stallergènes SA ^*

Author keywords

Allergy; Asthma; Corticosteroids; House dust mite; Sublingual immunotherapy

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CETIRIZINE; CORTICOSTEROID; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN G4 ANTIBODY; LORATADINE; PLACEBO; PREDNISOLONE; TERBUTALINE; UNCLASSIFIED DRUG;

ADOLESCENT; ALLERGIC ASTHMA; ANAPHYLAXIS; ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOPHAGOIDES; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOTHERAPY; LIP SWELLING; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MOUTH ITCHING; MULTIPLE ORGAN FAILURE; NOCTURNAL ASTHMA; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCORING SYSTEM; SKIN SENSITIVITY; SYMPTOMATOLOGY;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ALLERGENS; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; CHILD; CHILD, PRESCHOOL; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PYROGLYPHIDAE; QUALITY OF LIFE;

EID: 33846939850     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/j.1399-3038.2006.00475.x     Document Type: Article

References (44)

1. PLATTS-MILLS TA, VERVLOET D, THOMAS WR, et al. Indoor allergens and asthma: report of the Third International Workshop. J Allergy Clin Immunol 1997: 100 (Suppl.): 2-24.
2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Bethesda, MD: NHLBI/WHO Workshop Report 1995 (publication no. 95-3659), 1995.
3. WARNER JO, PRICE JF, SOOTHILL JF, et al. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978: 2: 912-5.
4. OLSEN O, LARSEN K, JACOBSEN L, et al. A one year placebo controlled double-blind house dust mite immunotherapy study in asthmatic adults. Allergy 1997: 52: 853-9.
5. HEDLIN G, WILLE S, BROWALDH L, et al. Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy. J Allergy Clin Immunol 1999: 103: 609-14.
6. GRUBER W, EBER E, MILEDER P, et al. Effect of immunotherapy with house dust mite extract on the bronchial responsiveness of paediatric asthma patients. Clin Exp Allergy 1999: 29: 176-81.
7. DES ROCHES A, PARADIS L, MÉ NARDO JL, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997, 99: 450-3.
8. PAJNO G, BARBIERO G, DE LUCA F, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mites by specific immunotherapy. A sixyear follow-up study. Clin Exp Allergy 2001: 31: 1392-7.
9. BOUSQUET J, LOCKEY RF, MALLING H-J. WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998: 53 (Suppl. 44): 1-42.
10. BOUSQUET J, VAN CAUWENBERGE P, KHALTAEV N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001: 108: S147-334.
11. CANONICA G. PASSALACQUA G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003: 111: 437-48.
12. PASSALACQUA G, GUERRA L, PASQUALI M, et al. Efficacy and safety of sublingual immunotherapy. Ann Allergy Asthma Immunol 2004: 93: 3-12
13. WILSON DR, TORRES LIMA M, DURHAM SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005: 60: 4-12.
14. KHINCHI M, POULSEN L, CARAT F, et al. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004: 58: 45-53.
15. TARI MG, MANCINO M, MONTI G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr) 1990: 18: 277-84.
16. HIRSCH TH, SÄHN M, LEUPOLD W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D. pt.) in children. Pediatr Allergy Immunol 1997: 8: 21-7.
17. BOUSQUET J, SCHEINMANN P, GUINNEPAIN M-T, et al. Sublingual-swallow immunotherapy in patients with asthma due to house dust mites: a double-blind placebocontrolled study. Allergy 1999: 54: 249-50.
18. PAJNO GB, MORABITO L, BARBERIO G, et al. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000: 55: 842-9.
19. BAHCECILER N, ISIK U, BARLAN I, et al. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind placebo-controlled study. Pediatr Pulmonol 2001: 32: 49-55.
20. MARCUCCI F, SENSI L, DI CARA G, et al. Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sublingual immunotherapy. Pediatr Allergy Immunol 2005: 16: 519-26.
21. TILL SJ, FRANCIS JN, NOURI-ARIA K, et al. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004: 113: 1025-34.
22. MOINGEON P, BATARD T, FADEL R, et al. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006: 61: 151-65.
23. WAALKENS HJ, VAN ESSEN-ZANDVLIET EE, HUGHES MD, et al. Cessation of long-term treatment with inhaled corticosteroids (budesonide) in children with asthma results in deterioration. Am Rev Respir Dis 1993: 148: 1252-7.
24. BACHARIER LB. "Step-down" therapy for asthma: why, when, and how? J Allergy Clin Immunol 2002: 109: 916-9.
25. HAWKINS G, MCMAHON AD, TWADDLE S, et al. Stepping down inhaled corticosteroids in asthma: a randomised controlled trial. Br Med J 2003: 326: 1115-8.
26. LIND P. Enzyme-linked immunosorbent assay for determination of major excrement allergens of house dust mite species D. pteronyssinus, D. farinae and D. microceras. Allergy 1986: 41: 442-51.
27. CLAVEL R, BOUSQUET J, ANDRÉ C, et al. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass pollen extract in rhinitis. Allergy 1998: 53: 493-8.
28. CHRISTIE MJ, FRENCH D, SOWDEN A, et al. Development of child-centered disease-specific questionnaires for living with asthma. Psychosom Med 1993: 55: 541-8.
29. ADKINSON NF Jr, EGGLESTON PA, ENEY D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997: 336: 324-31.
30. MAESTRELLI P, ZANOLLA P, POZZAN M, et al. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mites. J Allergy Clin Immunol 2004: 113: 643-9.
31. ANDRÉ C, PERRIN-FAYOLLE M, GROSCLAUDE M, et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Int Arch Allergy Immunol 2003: 131: 111-8.
32. TONNEL AB, SCHERPEREEL A, DOUAY B, et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004: 59: 491-7.
33. MORGAN WJ, CRAIN EF, GRUCHALLA RS, et al. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med 2004: 351: 1068-80.
34. LUCZINSKA C, TREDWELL E, SMEETON N, BURNEY P. A randomized controlled trial of mite allergen-impermeable bed covers in adult mite-sensitized asthmatics. Clin Exp Allergy 2003: 33: 1648-53.
35. BAHCECILER NN, ARIKAN C, TAYLOR A, et al. Impact of sublingual immunotherapy on specific antibody mevels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005: 136: 287-94.
36. ALLAM JP, NOVAK N, FUCHS C et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive Fc-epsilon RI expression. J Allergy Clin Immunol 2003: 112: 141-8.
37. PLAUT M, ROTROSEN D. Tolerance induced by allergen immunotherapy. Clin Allergy Immunol 2004: 18: 681-702.
38. GROSCLAUDE M, BOUILLOT P, ALT R, et al. Safety of various dosage regimens during induction of sublingual immunotherapy. Int Arch Allergy Immunol 2002: 129: 248-53.
39. PAJNO GB, PERONI DG, PEITROBELLI D, et al. Safety of sublingual immunotherapy in children with asthma. Pediatr Drugs 2003: 5: 777-81.
40. GIDARO GB, MARCUCCI F, SENSI L, et al. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005: 35: 565-71.
41. MAROGNA M, MASSOLO A, SPADOLINI I, et al. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy 2004: 59: 1205-10.
42. MÖLLER C, DREBORG S, FERDOUSI HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinocojunctivitis (The PAT - study). J Allergy Clin Immunol 2002: 109: 251-6.
43. NOVEMBRE E, GALLI E, LANDI F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinocojunctivitis. J Allergy Clin Immunol 2004: 114: 851-7.
44. GUILBERT TW, MORGAN WJ, ZEIGER RS, et al. Longterm inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006: 354: 1985-97.